Preclinical
If you’re exploring nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) or cancer-associated liver fibrosis, you may want to learn about TD2’s latest murine model: liver fibrosis induced by a choline-deficient, L-amino acid-defined, high-fat diet. The new model is the latest in a series of liver fibrosis animal models TD2 has in its catalogue, that...
Ketogenic diets—which involve higher saturated fat, moderate protein and low carbohydrate consumption—have been successfully used to manage human...
Often, new drug makers come across a potential anticancer agent—and as they consider evaluating that agent further, they tend to confront this...
Oncology drug development is important for numerous drug developers, funding bodies and academic researchers. This has caused a wealth of new...
A Q&A with Paul Gonzales of TD2 on the essentials for preclinical success—and what researchers should know going into every project. Q. What...
